… other complications. On April 10, 2012, Corcept Therapeutics Incorporated ( CORT ) announced that Korlym (mifepristone ..... the company's Chief Executive Officer, Corcept Therapeutics , will be the sole marketer of Korlym. A …
Leerink Swann says the pricing for Corcept 's ( CORT -0.8% ) Korlym is higher than expected at $186 per 300mg tablet, which should help offset its caution regarding patient numbers …
By M.E. Garza : If you stayed long Corcept Therapeutics (NASDAQ: CORT ) even as others advised you against it ..... proudly all the way to the bank. Shares of Corcept Therapeutics Inc. surged as high as $4.90 and managed …
Corcept Therapeutics ( CORT ) continues to skyrocket after landing FDA approval for its Korlym oral medicine used to treat Cushing's syndrome patients …
Feb 17 (Reuters) - U.S. health regulators approved Corcept Therapeutics 's Korlym, the first oral drug designed to treat a rare hormonal disorder called Cushing's syndrome.
By Brian L. Wilson : Corcept Therapeutics ( CORT ) is a drug discovery company ..... either exogenous or endogenous. Corcept is looking to treat the more problematic ..... fewer than 200,000 affected), Corcept will be given special privileges …
… shortly before the FDA’s decision. Here are 3 stocks that are not overextended with ample room for upside. Corcept Therapeutics ( CORT ) has a PDUFA date on 2/17/12 for Corlux for Cushing's Syndrome. Cushing's Syndrome results from prolonged …
Corcept Therapeutics ( CORT -8.7% ) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively . Post your comment!
… Therapeutics ( CTICD , press release ) +2.8% , Exelixis ( EXEL , PR ) -2.2% , Incyte ( INCY , PR ) +3% , Corcept Therapeutics ( CORT , PR ) -4.8% , United Therapeutics ( UTHR , PR ) -6.1% , RXi Pharmaceuticals ( RXII , PR ) +17.7 …